National Medical Products Administration and China National Intellectual Property Administration, Implementing Measures for the Mechanism for the Early Resolution of Pharmaceutical Patent Disputes (Trial Implementation)

国家药品监督管理局、国家知识产权局药品专利纠纷早期解决机制实施办法 (试行)

August 06, 2021 | BY

Susan Mok

An early resolution mechanism is in place for pharmaceutical patent disputes

Promulgated: July 4, 2021

Effective: as of date of promulgation

Main contents: When a chemical generic drug applicant submits an application for pharmaceutical marketing authorization, it shall compare the patent information disclosed on China's marketed pharmaceutical patent information registration platform and make a statement on each pharmaceutical patent related to the brand name drug. Statements are divided into four categories:

This premium content is reserved for
China Law & Practice Subscribers.

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]